For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

It’s exceedingly expensive to own a pet, prompting owners to delay veterinary visits or reconsider adopting one in the first place. Yet, animal health companies’ earnings keep growing.That’s down to the unwavering love between owners and their pets.While some owners might extend the time between their pets’ annual wellness visits to save money, they’ll shell out when their darling is truly sick or hurt, and that care is often the most expensive — and lucrative.Last year, Matthew Joseph, a 41-year-old New Yo ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Zoetis (ZTS) .Zoetis currently has an average brokerage recommendation (ABR) of 1.92, on a scal ...

Core Insights - Diamond Hill Capital's "Mid Strategy" reported a strong performance in Q4 2025, with a return of 3.65% compared to the Russell Midcap Index's 0.16% [1] - The strategy's year-to-date return was 13.47%, outperforming the Russell Midcap Index's 10.60% [1] - AI-related spending was a significant driver in equity markets, although investor caution emerged in December 2025 [1] Company Overview: Zoetis Inc. (NYSE:ZTS) - Zoetis Inc. is a leader in the animal health market, focusing on medications, vaccines, and diagnostic products for both companion animals and livestock [3] - As of March 17, 2026, Zoetis Inc. shares closed at $121.68, with a market capitalization of approximately $53.624 billion [2] - The stock experienced a -5.77% return in the past month and a -25.69% decline over the past twelve months [2] Investment Positioning - Concerns regarding an arthritis drug for dogs have negatively impacted Zoetis Inc.'s share price, creating an opportunity for investment below intrinsic value estimates [3] - Despite its potential, Zoetis Inc. is not among the 40 most popular stocks among hedge funds, with 69 hedge fund portfolios holding the stock at the end of Q4, down from 72 in the previous quarter [4] - The company is viewed as having less upside potential compared to certain AI stocks, which are considered to carry less downside risk [4]

Group 1 - The company is guiding for 3.5% organic constant currency growth this year, following a 6% growth in 2025, indicating a diverse portfolio will drive this growth [1] - Core therapeutic areas include dermatology, parasitology, and pain management, with expectations for pain to return to growth in 2026, while parasitology is anticipated to lead growth this year due to increased competition in dermatology [2] - The diagnostics segment is performing well, and the livestock sector is highlighted as a bright spot, historically growing at 2% to 4% [3]

Summary of Zoetis 2026 Conference Call Company Overview - **Company**: Zoetis (NYSE: ZTS) - **Date**: March 17, 2026 - **Speaker**: Kristin Peck, CEO Key Points Industry and Company Guidance - **2026 Guidance**: Zoetis is guiding for 3.5% organic constant currency growth after achieving 6% in 2025 [1] - **Growth Drivers**: The growth will be driven by a diverse portfolio, particularly in core therapeutic areas such as dermatology, parasiticides, and pain management [2][3] - **Livestock Growth**: Historically, livestock growth has been around 2%-4%, but Zoetis has seen mid- to high-single-digit growth over the past three years and expects to outperform the market in 2026 [3] Financial Metrics - **Price and Volume Assumptions**: The company expects 2%-3% growth from price increases and the remainder from volume for 2026 [5] - **Vet Clinic Visits**: Despite a decline in visits, spending at vet clinics grew by 6% in Q4 2025, indicating a strong human-animal bond and willingness to spend on pet care [10][11] Competitive Landscape - **Market Competition**: Increased competition in dermatology and parasiticides is expected, but Zoetis remains confident in its brand loyalty and customer satisfaction [57][58] - **New Products**: The company is focusing on long-acting pain products and expects to launch new therapies in oncology, cardiology, and renal health, which are anticipated to be high-value markets [19][20][21] Supply Chain and External Factors - **Impact of Oil Prices**: The ongoing conflict in Iran has minimal direct sales impact (less than 1% of total sales), but rising oil prices could affect shipping costs [7][9] - **Weather Impact**: Q1 2026 has seen adverse weather conditions affecting the parasiticide market, which typically performs better in Q2 and Q3 [55][56] Innovation and R&D - **AI in Drug Discovery**: Zoetis is leveraging AI for early drug discovery and molecule selection, utilizing unique datasets that include clinical trial data and genetic information [49][50][51] - **Future Products**: The company is optimistic about the potential of new products in renal health, which is projected to be a $3-$4 billion market, contingent on improved diagnostic rates [20][31] Market Trends - **Protein Demand**: The growing global population and middle-class expansion are driving protein demand, with poultry, fish, and pork being the fastest-growing sources [35][36] - **Health and Wellness Trends**: An aging population is increasing the focus on health and wellness, which is expected to support protein consumption trends [44] Strategic Changes - **Field Team Restructuring**: Zoetis has restructured its go-to-market teams to enhance reach and frequency, focusing on specialty products and chronic care [46][48] Long-Term Outlook - **2030 Vision**: Zoetis aims to continue growing its core franchises while exploring new therapeutic areas, emphasizing the importance of portfolio diversity and innovation [60][61] Additional Insights - **Customer Satisfaction**: High customer satisfaction rates (80%-90%) for key products like Apoquel and Simparica indicate strong brand loyalty [14][58] - **Veterinary Engagement**: The company is investing in professional service vets to enhance scientific conversations and support the growth of specialty products [48] This summary encapsulates the key insights and strategic directions discussed during the Zoetis 2026 conference call, highlighting the company's growth prospects, competitive landscape, and innovation strategies.

Company Overview - Zoetis Inc. (ZTS) is identified as a wide-moat company operating in a highly attractive industry with significant opportunities for profitable growth in the future [1] - The market is currently pricing Zoetis at below-average multiples, even lower than those of weaker competitors [1] Investment Analysis - The analysis emphasizes the importance of understanding what drives a company's economics, including competitive positioning, unit economics, margins, reinvestment needs, and balance sheet health [1] - Valuation is considered a crucial part of the investment process, not merely as a single "fair value" number, but as a means to comprehend what the current price implies and the conditions necessary for the investment to be viable [1]

Core Viewpoint - Zoetis (ZTS) has experienced significant selling pressure, resulting in an 8.1% decline over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if ZTS is oversold, with a current reading of 29.54, suggesting that selling pressure may be exhausting and a rebound could occur [2][5]. - RSI is a momentum oscillator that measures price movement speed and change, typically indicating oversold conditions when below 30 [2][3]. Group 2: Fundamental Indicators - Analysts have raised earnings estimates for ZTS by 3.2% over the last 30 days, which often correlates with price appreciation in the near term [7]. - ZTS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, further supporting the potential for a turnaround [8].

Group 1 - The company reported a strong fiscal year 2025 with a 6% growth in revenue on an organic operational basis [2] - The bottom line also showed a 7% increase year-over-year, indicating strong financial discipline throughout the profit and loss statement [2] - The growth was characterized by a tale of two halves, with the first half achieving 9% growth, while the second half saw a decline to 6% due to various factors [2] Group 2 - There was noted weakness in the U.S. consumer market, which impacted overall performance [3]

Summary of Zoetis Conference Call Company Overview - **Company**: Zoetis - **Industry**: Animal Health Key Financial Performance - **Fiscal Year 2025**: - Top line growth of **6%** on an organic operational basis - Bottom line growth of **7%** - Growth was **9%** in the first half and **6%** in the second half of the year [4][5] - **Fiscal Year 2026 Guidance**: - Expected top line growth between **3% and 5%** - Expected bottom line growth between **3% and 6%** [5][6] Market Dynamics - **Consumer Behavior**: - Weakness observed in the U.S. consumer market, particularly affecting pet care - Consumers are spending more on animal health, but this is driven by higher prices rather than volume [5][9] - **Livestock Portfolio**: - Continued strong growth in livestock, with growth rates of **6%**, **5%**, and **7%** over the past three years - Expected to grow in the mid-single digits in 2026, outpacing companion animal growth [5][6][16] Competitive Landscape - **Pet Care Market**: - Competitive dynamics have impacted growth, particularly in the second half of 2025 - Price increases have affected Gen Z and millennials, leading to reduced volume [7][9] - **International Business**: - International companion animal business has shown growth similar to the U.S. market - Significant opportunities exist in international markets, particularly in livestock [14][15] Product Segments - **Parasiticides**: - Global market size of nearly **$7 billion** - Triple combination products have gained significant market share, now accounting for **50%** of U.S. clinic patient share [25][26][28] - Trio product generated **$1 billion** in revenues in the U.S. last year [28] - **Dermatology**: - Revenues reached **$1.7 billion** in 2025, with room for further expansion - Competitive pressures and a decrease in therapeutic visits impacted growth in the second half of 2025 [42][43] Pipeline and Future Growth - **Pipeline Focus**: - Key areas include chronic kidney disease, oncology, cardiology, and obesity, representing a **$7 billion** total addressable market opportunity [53] - Ongoing R&D efforts to expand existing markets and address unmet needs in animal health [54][55] Capital Allocation Strategy - **Investment Priorities**: - Focus on investing in the business, including R&D and M&A - Share repurchase program remains a priority, with **$2.4 billion** remaining on the authorization [62][63] Conclusion - **Outlook for 2026**: - Despite headwinds, Zoetis remains optimistic about growth opportunities in both the companion and livestock segments - The company is well-positioned to leverage its product pipeline and market leadership to drive future growth [66][67]